Thyroid disorders and occurrence of Nonorgan-specific Autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1)

Journal of Clinical Gastroenterology

Volumn 43, Issue 5, 2009, Pages 470-476

  Hass, Holger G ^a   Klein, Reinhild ^c   Nehls, Oliver ^b   Kaiser, Stephan ^c  

^a MARIENHOSPITAL STUTTGART   (Germany)

^b Centre Bad Cannstatt   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Consensus interferon; Dysthyroidism; High dose induction; Nonorganspecific autoantibodies (NOSA)

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CONSENSUS INTERFERON; NONORGAN SPECIFIC ANTIBODY; RIBAVIRIN; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHIATRIC SI; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; WEAKNESS;

ANTIVIRAL AGENTS; AUTOANTIBODIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPERTHYROIDISM; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; RNA, VIRAL; THYROID DISEASES; THYROID GLAND; THYROIDITIS; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67651113775     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318184a470     Document Type: Article

References (30)

1. Lindsay KL, Trepo C, Heintges T, et al. Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34:395-403.
2. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa- 2a in patients with chronic hepatitis C. N Engl J Med. 2000; 343:1666-1672.
3. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-a-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endo Metabol. 2001;86:1925-1929. (Pubitemid 32472899)
4. Wong V, Fu AX, George J, et al. Thyreotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol. 2002;56:793-798. (Pubitemid 34785912)
5. Passos de Souza E, Evangelista-Segundo PT, Jose FF, et al. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol. 2001;20:297-299. (Pubitemid 32776481)
6. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut. 2001;48:378-383. (Pubitemid 32269567)
7. Cammarota G, Cuoco L, Cianci R, et al. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet. 2000;356:1494-1495. (Pubitemid 30822096)
8. McMurray RW. Hepatitis C-associated autoimmune disorders. Rheum Dis Clin North Am. 1998;24:353-374.
9. Eisenbart GS. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004;111:225-233.
10. Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun. 2000;14:189-193. (Pubitemid 30662578)
11. Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular cha-racterization of a novel synthetic interferonalpha species, consensus interferon. J Interferon Cytokine Res. 1996;16:489-499.
12. Kaiser S, Hass HG, Gregor M. Successful retreatment of Peginterferon Nonresponder Patients with Chronic Hepatitis C with High Dose Consensus Interferon Induction Therapy [abstract]. Presented at the Digestive Disease Week (DDW); May 16-20, 2004;New Orleans.
13. Kaiser S, Hass HG, Lutze B, et al. Comparison of Daily Consensus Interferon versus Peginterferon alfa 2a Extended Therapy of 72 Weeks for Peginterferon/Ribavirin Relapse Patients with Chronic Hepatitis C [abstract]. Presented at the Digestive Disease Week (DDW); May 21-24, 2006; Los Angeles, CA.
14. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in nonresponder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006;44:291-301. (Pubitemid 43069210)
15. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective ceries of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253-257. (Pubitemid 23225092)
16. Marazuela M, Garcia-Buey L, Gonzales-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol. 1996;44:635-642. (Pubitemid 26225178)
17. Peoćh K, Dubel L, Chazouilleres O, et al. Polyspecificity of antimicrosomal thyroid antibodies in hepatitis C virus-related infection. Am J Gastroenterol. 2001;96:2978-2983. (Pubitemid 32959542)
18. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs. hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445-1448. (Pubitemid 28317761)
19. Carella C, Maziotti G, Amato G, et al. Interferon-a-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89: 3656-3661. (Pubitemid 39071450)
20. Volzke H, Ludemann J, Robinson DM, et al. The prevalence of undiagnosed thyroid disorders in a previously iodinedeficient area. Thyroid. 2003;13:803-810. (Pubitemid 37070159)
21. Seck T, Scheidt-Nave C, Ziegler R, et al. Prevalence of thyroid gland dysfunctions in 50 to 80-year-old patients. An epidemiologic cross-sectional study in a southwestern community. Med Klin. 1997;92:642-646.
22. Deutsch M, Dourakis S, Manesis E, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology. 1997;26: 206-210. (Pubitemid 27280326)
23. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha. Gastroenterology. 1992; 102:2155-2160.
24. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCVrelated chronic hepatitis: a prospective study. J Endocrinol Invest. 2002;25:624-630. (Pubitemid 34784743)
25. Marceau G, Lapierre P, Beland K, et al. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology. 2005;42:675-682.
26. Gatselis NK, Georgiadou SP, Tassopoulos N, et al. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol. 2005;11: 482-487. (Pubitemid 40185579)
27. Wasmuth HE, Stolte C, Geier A, et al. The presence of nonorgan- specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis. 2004;4:4. (Pubitemid 38671476)
28. Noda K, Enomoto N, Arai K, et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol. 1996;31:716-722. (Pubitemid 26290938)
29. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut. 2001;49: 596-597.
30. Betterle C, Fabris P, Zanchetta R, et al. Auto-immunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2001;23:1125-1126.